v3.25.1
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2025
Mar. 31, 2024
Operating expenses:        
Research and development $ 15,283 $ 12,401 $ 40,664 $ 36,654
General and administrative 4,740 3,812 13,380 10,667
Total operating expenses 20,023 16,213 54,044 47,321
Operating loss (20,023) (16,213) (54,044) (47,321)
Non-operating income (expense):        
Interest and other income, net 1,115 1,122 4,037 3,829
Loss from change in fair value of derivative liabilities (6) (1,959) (15) (1,991)
Total non-operating income (expense), net 1,109 (837) 4,022 1,838
Net loss (18,914) (17,050) (50,022) (45,483)
Other comprehensive income (loss):        
Net unrealized gain (loss) on marketable debt securities (21) (30) 122 273
Comprehensive loss $ (18,935) $ (17,080) $ (49,900) $ (45,210)
Net loss per common share - basic (in dollars per share) $ (0.27) $ (0.34) $ (0.72) $ (0.89)
Net loss per common share - diluted (in dollars per share) $ (0.27) $ (0.34) $ (0.72) $ (0.89)
Weighted average number of common shares outstanding - basic (in shares) 70,031,041 50,812,332 69,901,565 51,211,564
Weighted average number of common shares outstanding - diluted (in shares) 70,031,041 50,812,332 69,901,565 51,211,564